Predicting COVID-19 Severity with a Specific Nucleocapsid Antibody plus Disease Risk Factor Score

Area of Science:

• Immunology
• Infectious Diseases
• Virology

Background:

• Predicting COVID-19 disease severity is crucial for patient management.
• Current prognostic tools for COVID-19 are limited, hindering effective early intervention.
• Identifying biomarkers for severe disease can improve patient outcomes.

Purpose of the Study:

• To identify specific antibody epitopes associated with severe COVID-19.
• To develop a prognostic tool for early identification of high-risk COVID-19 patients.
• To correlate antibody responses with clinical outcomes and patient comorbidities.

Main Methods:

• Enzyme-linked immunosorbent assay (ELISA) and coronavirus antigen microarray (COVAM) were used to map antibody epitopes in COVID-19 patient plasma.
• Antibody responses against nucleocapsid protein epitopes were analyzed.
• A disease risk factor score incorporating age and comorbidities was calculated for each patient.

Main Results:

• Antibodies to a 21-residue nucleocapsid epitope (Ep9) were associated with severe COVID-19, including ICU admission, ventilation, or death.
• Anti-Ep9 antibodies were detectable as early as 1-6 days post-symptom onset.
• A combination of anti-Ep9 antibodies and a risk factor score >3.0 predicted severe outcomes with 96.7% specificity.

Conclusions:

• The identification of anti-Ep9 antibodies provides a potential biomarker for severe COVID-19.
• A prognostic tool combining anti-Ep9 antibody detection and a risk factor score can aid in early risk stratification.
• This approach may facilitate timely therapeutic interventions for high-risk COVID-19 patients.